Larvol Veri

BIOMARKER:

KRAS G13

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

KRAS G13 KRAS G13	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G13 KRAS G13	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
KRAS G13 KRAS G13	Colorectal Cancer CRC	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
KRAS G13 KRAS G13	Colorectal Cancer CRC	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
KRAS G13 KRAS G13	Colorectal Cancer CRC	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G13 KRAS G13	Colorectal Cancer CRC	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D